Tremfya's Promising
Tremfya's Promising Debut Boosts Momentum for IL-23 Class in Ulcerative Colitis Treatment, According to Spherix Global Insights
15. November 2024 09:38 ET | Spherix Global Insights
EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- In what has been a transformative year for ulcerative colitis (UC) treatment, the IL-23 class has solidified its role as a key therapeutic treatment...
Exciting Advances in
Exciting Advances in Ulcerative Colitis Treatments: Skyrizi Gains Early Momentum Following FDA Approval in June
01. Oktober 2024 10:51 ET | Spherix Global Insights
EXTON, PA, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The past twelve months have been transformative for the rapidly evolving ulcerative colitis (UC) market, with a surge in advanced therapies receiving FDA...
Takeda’s Eohilia See
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, According to Spherix Global Insights
18. Juli 2024 10:05 ET | Spherix Global Insights
EXTON, PA, July 18, 2024 (GLOBE NEWSWIRE) -- In February of this year, Takeda’s Eohilia (budesonide oral suspension) received FDA approval as the first and only oral therapy for eosinophilic...
Maryland’s Largest Independent GI Provider Announces Grand Re-Opening Near Bowie
29. April 2019 06:05 ET | Capital Digestive Care
Silver Spring, MD, April 29, 2019 (GLOBE NEWSWIRE) -- Capital Digestive Care has announced it will reopen its Glenn Dale, MD office to serve patients in Prince George’s County.  Five of the area’s...